

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Claims for filing in US:

1-23 cancelled.

24. (New) Use of a proton pump inhibitor in the manufacture of a medicament for ingestion for the treatment or prophylaxis of a cancerous condition other than gastric cancer, further comprising an antacid.

25. (New) Use according to claim 24, wherein the condition is a tumour.

26. (New) Use according to claim 25, wherein the tumour is metastatic.

27. (New) Use according to claim 24, wherein the proton pump inhibitor is a 2-pyridyl methylsulphonyl benzimidazole proton pump inhibitor.

28. (New) Use according to claim 27, wherein the proton pump inhibitor is selected from omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole, and mixtures thereof.

29. (New) Use according to claim 24, wherein the medicament is for oral administration and is for the treatment of a patient who has been treated with an antacid sufficient to prevent total sequestration of the proton pump inhibitor in the stomach of the patient.

30. (New) Use according to claim 28, wherein the antacid is formulated for administration prior to the proton pump inhibitor.

31. (New) Use according to claim 28, wherein the antacid is calcium carbonate.

32. (New) Use according to claim 28, wherein the antacid is an H₂-receptor antagonist.

33. (New) Use of a proton pump inhibitor in the manufacture of a medicament for combination therapy or prophylaxis of a disease condition other than a gastric disease condition, wherein the proton pump inhibitor is administered prior to at least one further drug indicated against said condition.
34. (New) Use according to claim 33, wherein administration of the proton pump inhibitor is sufficiently prior to the administration of the further drug as to reduce the acidity associated with the site of the said condition.
35. (New) Use according to claim 33, wherein the period prior to administration of the further drug is between 30 minutes and 3 days.
36. (New) Use according to claim 33, wherein the further drug is selected from: vinka alkaloids; taxanes; anthracyclines; anthracenes; epipodophyllotoxins; camptothecins; heavy metal oxyanions; actinomycin d; mitomycin c; methotrexate; trimetrexate; amsacrine; imitinib; and melphalan; 5-fluorouracil; and cisplatin.
37. (New) Use according to claim 33, wherein the disease condition is resistant to the further drug, and the proton pump inhibitor medicament is for administration at a time when levels of the further drug are clinically sub-effective.
38. (New) Use according to claim 37, wherein the disease condition is a cancerous condition.
39. (New) Use according to claim 38, wherein the condition is a tumour.
40. (New) Use according to claim 39, wherein the tumour is metastatic.
41. (New) Use according to claim 37, wherein the disease condition is selected from AIDS, rheumatoid arthritis, ulcerative colitis, Crohn's disease, or combinations thereof.
42. (New) Use according to claim 41, wherein the condition is AIDS, and the further drug is an HAART drug.
43. (New) Use according to claim 33, wherein the proton pump inhibitor is a 2-

pyridyl methylsulphonyl benzimidazole proton pump inhibitor.

- 44. (New) Use according to claim 43, wherein the proton pump inhibitor is selected from omeprazole, lansoprazole, pantoprazole, esomeprazole, rabeprazole, and mixtures thereof.
- 45. (New) Use according to claim 33, further comprising an antacid.
- 46. (New) Use according to claim 24, wherein the proton pump inhibitor is omeprazole.
- 47. (New) Use according to claim 33, wherein the proton pump inhibitor is omeprazole.
- 48. (New) Use according to claim 24, wherein the medicament is for the treatment of the condition.
- 49. (New) Use according to claim 33, wherein the medicament is for the treatment of the condition.